Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity

@article{Thomsen2007ProlongedAO,
  title={Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity},
  author={J. J. Thomsen and R. Rentsch and P. Robach and J. Calbet and R. Boushel and P. Rasmussen and C. Juel and C. Lundby},
  journal={European Journal of Applied Physiology},
  year={2007},
  volume={101},
  pages={481-486}
}
The effects of recombinant human erythropoietin (rHuEpo) treatment on aerobic power (VO2max) are well documented, but little is known about the effects of rHuEpo on submaximal exercise performance. The present study investigated the effect on performance (ergometer cycling, 20–30 min at 80% of maximal attainable workload), and for this purpose eight subjects received either 5,000 IU rHuEpo or placebo every second day for 14 days, and subsequently a single dose of 5,000 IU/placebo weekly/10… Expand
The Performance Effects of Microdose Recombinant Human Erythropoietin Administration and Carbon Monoxide Rebreathing
TLDR
Assessment of the effects on maximal oxygen uptake (V˙O2max) and RSA of two interventions known to differentially influence blood oxygen carrying capacity found that carbon monoxide (CO) inhalation should inhibit RSA. Expand
Mechanism by which rHuEPO improves submaximal exercise performance
  • T. Noakes
  • Medicine
  • European Journal of Applied Physiology
  • 2008
TLDR
If the (submaximal) cardiac output is appropriate so that oxygen supply is indeed optimal during prolonged exercise in healthy humans then, as acknowledged by the authors, rHuEPO administration must improve submaximal endurance performance by mechanisms other than increasing oxygen delivery to the exercising muscles. Expand
Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport?
TLDR
In healthy humans, rHuEpo increases maximal oxygen consumption due to augmented systemic and muscular peak oxygen delivery, and the augmented hematocrit did not compromise peak cardiac output. Expand
Erythropoietin enhances whole body lipid oxidation during prolonged exercise in humans
TLDR
EPO can modulate substrate utilization during exercise, leading to enhanced fat utilization and lower use of carbohydrates, which opens new research directions exploring whether systemic EPO levels, in physiological conditions, participate to the modulation of fat oxidation. Expand
Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men
TLDR
Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline, and field performance effects coincided with r HuEpo-induced elevated O2 max and Hbmass. Expand
Effects of human recombinant erythropoietin on endurance performance : real and imagined
TLDR
The overall aim of this thesis was to determine the effects of administration of recombinant human erythropoietin ( r-HuEpo) on endurance performance and to explore the psychosocial effects of taking this drug and the validity of the Cosmed K4b2 portable metabolic analyser in measuring VO2 during submaximal and maximal running velocities in an outdoor environment. Expand
The Ergogenic Effect of Recombinant Human Erythropoietin on V̇O2max Depends on the Severity of Arterial Hypoxemia
TLDR
The mechanism highlighted by the data is that besides its strong influence on CaO2, rhEpo was found to enhance leg V̇O2max in normoxia through a preferential redistribution of cardiac output toward the exercising legs, whereas this advantageous effect disappeared during severe hypoxia, leaving augmentedCaO2 alone insufficient for improving peak leg O2 delivery and V̧O2. Expand
Erythropoietin does not reduce plasma lactate, H+, and K+ during intense exercise
TLDR
In conclusion, rHuEPO does not reduce plasma accumulation of lactate, H+, and K+ at work rates corresponding to ∼80% of peak power output. Expand
Low doses of recombinant human erythropoietin does not affect C-terminal FGF23 in healthy men.
TLDR
It is demonstrated that cFGF23 is not sensitive to low doses of subcutaneous rhEpo injections in healthy males and the effect of more frequent low doses is unknown. Expand
Effects of EPO on Blood Parameters and Running Performance in Kenyan Athletes
TLDR
Four weeks of rHuEpo increased the HGB and HCT of Kenyan endurance runners to a lesser extent than in SCO (~17% vs ~10%, respectively) and these alterations were associated with similar improvements in running performance immediately after the r HuEpo administration and 4 wk after the final injection. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise
TLDR
The ability of low doses of r-HuEPO to maintain Hct and haematocrit at elevated levels is confirmed. Expand
Effect of rhEPO administration on serum levels of sTfR and cycling performance.
TLDR
Serum levels of sTfR may be used as an indirect marker of supranormal erythropoiesis up to 1 wk after the administration of rhEPO, but the effects on endurance performance outlast the increase in sTFR. Expand
Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men
TLDR
In conclusion, low doses of rhEpo increased Hb levels and Hct by more than 10% after 6 weeks, and induced a markedly accentuated blood pressure reaction during exercise. Expand
Effects of recombinant human erythropoietin injections on physical self in endurance athletes
TLDR
The main psychological result was that endurance athletes were highly sensitive to the effects of rHuEPO on physical fitness and the perception of increased physical condition may lead to a stronger commitment to training. Expand
Effects of erythropoietin administration in training athletes and possible indirect detection in doping control.
TLDR
A method based on the measurement in blood samples of the sTfR/serum protein ratio to determine if the observed values of this marker are related to rHuEpo abuse is proposed. Expand
Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume
TLDR
Epo treatment in healthy humans induces an elevation in haemoglobin concentration by two mechanisms: (i) an increase in red cell volume; and (ii) a decrease in plasma volume, which is probably mediated by a downregulation of the rennin–angiotensin–aldosterone axis. Expand
Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers.
TLDR
A double-blind, placebo-controlled study of the pharmacokinetics and safety of multiple doses of recombinant human erythropoietin in normal male subjects demonstrated that rHuEPO had a dose-related effect on the hematocrit independent of the route of administration and thatmultiple doses of rHu EPO had no direct pressor effects. Expand
Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis.
TLDR
It is confirmed that r-HuEPO administration causes a predictable and reproducible hematologic response and this work establishes an indirect blood test which offers a useful means of detecting and deterring r- HuEPO abuse. Expand
The effects of red blood cell infusion on 10-km race time.
TLDR
Erythrocythemia induced by the infusion of 400 mL of autologous packed RBCs effectively increased performance capacity in a 10-km track race, probably due to an increase in oxygen delivery to the working muscles. Expand
Limitations to VO2max in humans after blood retransfusion.
TLDR
The relative increase in VO2max after blood retransfusion matched therelative increase in 'aerobic performance', measured as the maximal power output that could be maintained aerobically for 30 min, and suggests that there is an inability to fully utilize muscle oxidative capacity in the normocythaemic state. Expand
...
1
2
3
...